BLRX Enrolls First Patient in GLIX1 Study
BioLineRx starts cancer treatment trial, shares rise. GLIX1 study underway.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Related stories
Black Diamond Group Reports C$159.9M Third-Quarter Revenue
Black Diamond Group reported third-quarter revenue of C$159.9 million.
M impact | EQUITY | Oct 29, 2026, 10:43 PM UTC
Amazon reports lower third-quarter profit
M impact | EQUITY | Oct 29, 2026, 10:34 PM UTC
Edison International Reports Quarterly Results
Edison International reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 10:34 PM UTC
São Paulo Stock Exchange Falls on Fiscal Fears After Lula’s Reelection
M impact | EQUITY | Oct 29, 2026, 10:34 PM UTC
Alphabet Falls as Wall Street Closes Lower
Alphabet fell as Wall Street closed lower.
L impact | EQUITY | Oct 29, 2026, 10:34 PM UTC
Ingersoll Rand Reports Quarterly Results Through September 30
Ingersoll Rand reported results for the quarter ended September 30; the supplied text contains no financial figures.
M impact | EQUITY | Oct 29, 2026, 10:33 PM UTC